Mineralys Therapeutics, Inc. MLYS 深 滬
已收盤 10-24 16:00:00 美东时间
39.90
-0.910
-2.23%
華盛通- 最 高41.46
- 今 開41.20
- 成交量 68.72万股
- 最 低 39.33
- 昨 收 40.81
- 總市值 26.45亿
- 52周最高 44.80
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 8.241
- 委 比 -85.67%
- 總股本 6629.52万
- 歷史最高 44.80
- 量 比 0.81
- 振 幅 5.22%
- 歷史最低 5.85
- 每 手 1
- 風險率 9.43%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Mineralys Therapeutics Presents Phase 2 Explore-CKD Trial Of Lorundrostat At ASN Kidney Week 2025
~ Late-breaking Phase 2 trial data evaluating the safety and efficacy of 25 mg of lorundrostat in participants with hypertension and comorbid CKD to be presented~~ Phase 3 data of the Launch-HTN Trial of lorundrostat to
10-21 20:08
Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 2 Explore-CKD Trial of Lorundrostat at American Society of Nephrology (ASN) Kidney Week 2025
Mineralys Therapeutics announced that Phase 2 and Phase 3 data for lorundrostat will be presented at ASN Kidney Week 2025. The Phase 2 Explore-CKD trial data on lorundrostat’s safety and efficacy in hypertension and CKD patients will be featured in a late-breaking session. Additionally, Phase 3 Launch-HTN trial data will be included in the “Best of JAMA and NEJM” presentation. Lorundrostat is an aldosterone synthase inhibitor targeting uncontroll...
10-21 12:00
Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension
Mineralys Therapeutics Inc.宣布完成了其Phase 2 EXPLORE-OSA试验的参与者入组，该试验评估其药物lorundrostat对伴有中重度阻塞性睡眠呼吸暂停（OSA）和高血压患者的疗效。公司预计将在2026年第一季度公布试验的顶端线结果。OSA与高血压密切相关，且现有治疗方法有限，存在显著未满足的医疗需求。Lorundrostat是一种高选择性醛固酮合成酶抑制剂，旨在通过减少醛固酮的产生来控制血压。此试验的成功可能为更多患者提供有效治疗选择。
09-30 12:00
Goldman's 48 potential M&A candidates
Deal activity will rise by 15% in 2026, according to Goldman Sachs. Strategist David Kostin says M&A activity will increase next year "alongside accelerating US economic growth, improving CEO confiden...
09-29 03:14
SA Asks: Which biotechs could be acquired by year's end?
The fourth quarter has historically been a busy time for the biopharma industry, with the sector generally seeing a significant uptick in M&A activity. We asked Seeking Alpha analysts Stephen Ayers ...
09-14 04:18
美股大行评级 | 潜在涨幅208.48%！HC Wainwright & Co.上调Microbot Medical目标价至12美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Microbot Medical"买入"评级，目标价从9美元升至12美元；Maxim Group：维持Neuphoria Therapeutics"买入"评级，目标价从18美元升至35美元
09-12 12:53
美股大行评级 | 潜在涨幅577.08%！Veritone获D. Boral Capital升目标价至26美元，维持"买入"评级
今日重点评级关注：D. Boral Capital：维持Veritone"买入"评级，目标价从6美元升至26美元；Guggenheim：维持Dianthus Therapeutics"买入"评级，目标价从92美元升至100美元
09-10 18:01
美股大行评级 | 潜在涨幅37.57%！Mama's Creations获Roth Capital升目标价至13美元，维持"买入"评级
今日重点评级关注：Roth Capital：维持Mama's Creations"买入"评级，目标价从10美元升至13美元；高盛：维持Mineralys Therapeutics"买入"评级，目标价从32美元升至52美元
09-10 09:47
美股周涨跌榜 | 医药牛股频出！细胞动力周涨幅达50%，新药迎关键进展；美国联合医疗周涨超31%
医药牛股频出！细胞动力周涨幅达50%，新药迎关键进展；美国联合医疗周涨超31%，肺纤维化治疗取得重大突破；Lululemon周跌17%，此前下调年度利润及销售额预期>>
09-06 10:02
Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need
Mineralys Therapeutics announced positive subgroup analysis from the Phase 3 Launch-HTN trial of lorundrostat, demonstrating significant blood pressure reduction across diverse high-risk populations, including Black/African American adults, older adults, women, and those with obesity, with a favorable safety profile. The trial, the largest in uncontrolled or resistant hypertension, enrolled 1,083 participants on 2-5 antihypertensives, achieving r...
09-05 13:00
